GXCPC1®

Articular cartilage plays a crucial role in reducing friction between bones and joint surfaces. Damage to this cartilage leads to osteoarthritis, resulting in joint pain, tenderness, stiffness, locking, and joint effusion. Gwo Xi Stem Cell Company's new drug, "GXCPC1®" has been shown in pharmacological studies to regenerate cartilage tissue.

GXCPC1® is an allogeneic adipose-derived stem cell (ADSC) therapy aimed at treating patients with osteoarthritis (OA). Pre-clinical research has demonstrated that GXCPC1® has significant therapeutic potential for regenerating cartilage, where the histological analysis confirmed the presence of newly formed cartilage tissue, and toxicological safety tests indicated no tumor formation. Clinical trials have progressed through phases I/II, and the results have been published.

In the clinical trials, GXCPC1® showed improvements in pain reduction, knee function, and overall tolerance after transplantation. Notably, subjects receiving a high dose of GXCPC1® (4 x 10^7 cells) exhibited significantly better outcomes, including WOMAC total scores, pain, stiffness, function subscales, the visual analog scale (VAS) for pain, and the SF-12 quality of life scale, compared with those in the low dose group (6.7 x 10^6 cells) during a 1 year follow-up (NCT03943576). The trials confirmed that intra-articular injection of ADSCs is safe and well-tolerated, offering a promising therapeutic alternative for treating knee OA.